Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today)

Probiodrug AG has acquired fellow German firm Ingenium Pharmaceuticals AG in a stock-based deal and has closed a €20.6 million (US$27.7 million) venture capital round at the same time, to fund both an in-house drug development program in Alzheimer's disease and a newly acquired program in inflammation. (BioWorld International)